Dersch R, Sommer H, Rauer S, Meerpohl J J
Department of Neurology, Medical Center-University of Freiburg, Breisacher Str. 64, 79104, Freiburg, Germany.
German Cochrane Centre, Medical Center-University of Freiburg, Berliner Allee 29, 79110, Freiburg, Germany.
J Neurol. 2016 Jan;263(1):17-24. doi: 10.1007/s00415-015-7923-0. Epub 2015 Oct 12.
Controversy exists about residual symptoms after pharmacological treatment of Lyme neuroborreliosis. Reports of disabling long-term sequels lead to concerns in patients and health care providers. We systematically reviewed the available evidence from studies reporting treatment of Lyme neuroborreliosis to assess the prevalence and spectrum of residual symptoms after treatment. A literature search was performed in three databases and three clinical trial registers to find eligible studies reporting on residual symptoms in patients after pharmacological treatment of LNB. Diagnosis must have been performed according to consensus-derived case definitions. No restrictions regarding study design or language were set. Symptom prevalence was pooled using a random-effects model. Forty-four eligible clinical trials and studies were found: 8 RCTs, 17 cohort studies, 2 case-control studies, and 17 case series. The follow-up period in the eligible studies ranged from 7 days to 20 years. The weighted mean proportion of residual symptoms was 28 % (95 % CI 23-34 %, n = 34 studies) for the latest reported time point. Prevalence of residual symptoms was statistically significantly higher in studies using the "possible" case definition (p = 0.0048). Cranial neuropathy, pain, paresis, cognitive disturbances, headache, and fatigue were statistically significantly lower in studies using the "probable/definite" case definition. LNB patients may experience residual symptoms after treatment with a prevalence of approximately 28 %. The prevalence and spectrum of residual symptoms differ according to the applied case definition. Symptoms like fatigue are not reported in studies using the "probable/definite" case definition. As the "possible" case definition is more unspecific, patients with other conditions may be included. Reports of debilitating fatigue and cognitive impairment after LNB, a "post-Lyme syndrome", could therefore be an artifact of unspecific case definitions in single studies.
莱姆病神经伯氏疏螺旋体病药物治疗后的残留症状存在争议。关于致残性长期后遗症的报告引起了患者和医疗服务提供者的关注。我们系统回顾了报告莱姆病神经伯氏疏螺旋体病治疗情况的研究中的现有证据,以评估治疗后残留症状的患病率和范围。在三个数据库和三个临床试验注册库中进行了文献检索,以找到报告莱姆病神经伯氏疏螺旋体病药物治疗后患者残留症状的符合条件的研究。诊断必须根据共识得出的病例定义进行。对研究设计或语言没有设置限制。使用随机效应模型汇总症状患病率。共找到44项符合条件的临床试验和研究:8项随机对照试验、17项队列研究、2项病例对照研究和17项病例系列研究。符合条件的研究的随访期从7天到20年不等。最新报告时间点的残留症状加权平均比例为28%(95%置信区间23%-34%,n = 34项研究)。使用“可能”病例定义的研究中,残留症状的患病率在统计学上显著更高(p = 0.0048)。在使用“很可能/确定”病例定义的研究中,颅神经病变、疼痛、轻瘫、认知障碍、头痛和疲劳在统计学上显著更低。莱姆病神经伯氏疏螺旋体病患者治疗后可能会出现残留症状,患病率约为28%。残留症状的患病率和范围根据所应用的病例定义而有所不同。在使用“很可能/确定”病例定义的研究中未报告疲劳等症状。由于“可能”病例定义更不具特异性,可能会纳入患有其他疾病的患者。因此,关于莱姆病神经伯氏疏螺旋体病后衰弱性疲劳和认知障碍(“莱姆病后综合征”)的报告可能是单个研究中不具特异性病例定义的人为产物。